CClinicalTrials.gg
RecruitingNCT06541990HARMONYUpdated Aug 29, 2025

Psychoeducational Intervention for Patients With Hepatocellular Carcinoma

An interventional study of HARMONY and Enhanced usual care in Hepatocellular Carcinoma, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-29.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Primary completion was expected by Jun 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Oct 2024; still recruiting 1 year 11 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to refine and pilot test HARMONY, a psychoeducational intervention for patients with newly diagnosed hepatocellular carcinoma (HCC).

Read the detailed description

There are two parts of this study. Study Part 1 is an open pilot study to refine HARMONY prior to larger-scale testing in a randomized controlled trial (RCT) setting. Study Part 1 is purely descriptive, as the investigators will use the data to refine HARMONY before proceeding to Study Part 2.

Study Part 2 is a pilot RCT to assess the feasibility and acceptability of conducting a randomized trial of HARMONY versus enhanced usual care. Participants will complete a baseline survey and then be randomized to HARMONY versus enhanced usual care (a supportive care resource guide). This record reflects the clinical trial component (Study Part 2), as feasibility and acceptability outcomes will be collected for this phase only.

02

Conditions studied

  • Hepatocellular Carcinoma
03

In context

Carcinoma, Hepatocellular

3,182 studies on the registry are indexed under Carcinoma, Hepatocellular; 953 are open to participants now.

This study's planned enrollment of 50 is close to the median of 55 across 2,298 interventional studies indexed under Carcinoma, Hepatocellular.

Browse Carcinoma, Hepatocellular studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,536 studies on the registry; 446 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 161 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age ≥18 years
  • New diagnosis of HCC within the last six months
  • Ability to complete study procedures English

Exclusion criteria

Exclusion Criteria:

  • Incidentally diagnosed with HCC after liver transplantation
  • Significant uncontrolled hepatic encephalopathy, cognitive impairment, or psychiatric disorder which will interfere with study participation
  • Patients near the end of life for whom hospice is recommended
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    HARMONY

    HARMONY is a psychoeducational intervention that consists of three one-on-one coaching sessions and a structured session workbook.

    Behavioral: HARMONY

  • Active comparator
    Enhanced usual care

    The enhanced usual care condition consists of a curated list of supportive care services for patients with HCC.

    Other: Enhanced usual care

Interventions

  • BehavioralHARMONY

    A psychoeducational intervention for patients with HCC

  • OtherEnhanced usual care

    A supportive care resource guide

06

What researchers measure

Primary outcomes

  1. Feasibility: study enrollment rate

    ≥40% enrollment among consecutive eligible patients

    Time frame: 10 weeks

Secondary outcomes

  1. Feasibility: intervention completion rate

    ≥50% completion of 2/3 intervention sessions in the HARMONY arm

    Time frame: 10 weeks

  2. Acceptability

    ≥70% of patients in the HARMONY arm reporting Client Satisfaction Questionnaire-8 (CSQ-8) scores at or above the midpoint score of 20 on a scale from 8-32

    Time frame: 10 weeks

07

Study locations

1 of 1 sites recruiting
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    • Kelsey Lau-Min, MD, MSCE · Contact · klau-min@mgh.harvard.edu · 857-367-1486
    • Kelsey Lau-Min, MD, MSCE · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06541990
Lead sponsor
Massachusetts General Hospital
Responsible party
Kelsey S. Lau-Min, MD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 7, 2024
Start date
Oct 28, 2024
Primary completion
Jun 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Aug 29, 2025

Study contacts

Kelsey Lau-Min
Contact
klau-min@mgh.harvard.edu
617-724-4000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion